Cytokine, Gingival Crevicular Fluid, Periodontal Diseases, Saliva
Conditions
Brief summary
Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters.
Detailed description
Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters. Materials and Methods: A total of 80 systemically healthy, non-smokers aged between 25 and 55 including 20 periodontally healthy individuals, 20 individuals with gingivitis, 20 individuals with Stage III Grade B periodontitis, and 20 individuals with Stage III Grade C periodontitis were involved in our study. Clinical parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP), were recorded. GCF and unstimulated saliva samples were collected from all participants. IL-36α levels were quantified using enzyme-linked immunosorbent assay (ELISA).
Interventions
DIAGNOSTIC_TESTCollection of fluid samples
Collection of Gingival crevicular fluid and saliva from all patients at baseline.
Sponsors
Ordu University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* at least 20 teeth * older than 18 years
Exclusion criteria
* any systemic disease * pregnant or lactating * history of radiotherapy or chemotherapy * used antibiotics or any anti-inflammatory medication * smokers * had undergone periodontal treatment within the previous 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IL-36α levels | Baseline | IL-36α levels in the gingival crevicular fluid (GCF) and saliva of the all groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque index (PI) | Baseline | to measure plaque level in all groups |
| Gingival index (GI) | Baseline | to measure the level of gingival inflammation in all groups |
| Probing pocket depth (PPD) | Baseline | to measure the level of soft and hard tissue destructionin all groups |
| Clinical attachment level (CAL) | Baseline | to measure the attachment loss level in all groups |
| Bleeding on probing (BOP) | Baseline | to measure the severity of bleeding in all groups |
Countries
Turkey (Türkiye)
Outcome results
None listed